[3] With the inclusion of the DAC additive, the drug has an estimated half-life of about 6 to 8 days in humans.

[3] CJC-1295 has been shown to extend the half-life and bioavailability of growth-hormone-releasing hormone 1-29 and stimulate insulin-like growth factor 1 secretion.

[6] The extended half-life is achieved through the addition of a drug affinity complex (DAC) that binds to albumin, thus prolonging the peptide's presence in the bloodstream.

[7][8][9] It is primarily used for its potential to stimulate the release of growth hormone (GH) from the pituitary gland.

[11][12] The attending physician of the trial believed that the most likely explanation for the incident was that the patient had asymptomatic coronary artery disease with plaque rupture and occlusion, and that the occurrence was unrelated to treatment with CJC-1295.